Despite China’s hopes of recovering and rebounding from an ongoing economic downturn and COVID-19 disruptions, sharply rising deaths and the lingering impact of the pandemic are continuing to cloud investment, bringing little relief to the biotech and pharma sector.
One executive at a Shanghai-based gene therapy firm told Scrip that investor sentiment remains chilly, despite clinical data for new...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

